[Disulfiram and L-dopa in patients with Parkinson's syndrome and in torsion dystonia].
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000627:therapeutic use*; D004221:Disulfiram / Q000008:administration & dosage / Q000627:therapeutic use*; D004357:Drug Synergism; D004422:Dystonia Musculorum Deformans / Q000188:drug therapy*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D002537:Intracranial Arteriosclerosis / Q000150:complications; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy* / Q000209:etiology
D000978:Antiparkinson Agents; D004295:Dihydroxyphenylalanine; D004221:Disulfiram
Disulfirán y L-dopa en enfermos con sindrome de Parkinson y en distonia de torsión.